Verdicts genuinely change. Free email alert the moment HQL's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
abrdn Life Sciences Investors
158 holdings · as of 2026-06-30 (3.4 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
NON-COMPLIANT At least 25.95% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 59% turns out to be. Matching more holdings can only raise this share, never lower it.
158 holdings, 52 matched (41% of weight). Portfolio as of 2026-06-30, filed 2026-08-28. Source: SEC Form N-PORT.
12.92% of this portfolio’s income is non-permissible — weighted across holdings, computed over 25% of portfolio weight (30 of 158 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| uniQure NV | UNSCREENED | 3.77% | no in-house ratios for this holding |
| Insmed Inc | UNSCREENED | 3.22% | no in-house ratios for this holding |
| VeraDermics Inc | UNSCREENED | 3.06% | no in-house ratios for this holding |
| PSNL Personalis Inc | NON_COMPLIANT | 3.00% | AAOIFI2.0% Usmani11.9% Dow Jones Islamic5.7% S&P Shariah8.0% MSCI Islamic11.9% MSCI Islamic M-Series8.0% FTSE Shariah0.0% |
| ARGX Argenx SE | COMPLIANT | 2.64% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Dyne Therapeutics Inc | UNSCREENED | 2.58% | no in-house ratios for this holding |
| Denali Therapeutics Inc | UNSCREENED | 2.46% | no in-house ratios for this holding |
| VERADERMICS, INC. | UNSCREENED | 1.95% | no in-house ratios for this holding |
| Abivax SA | UNSCREENED | 1.90% | no in-house ratios for this holding |
| Immunovant Inc | UNSCREENED | 1.89% | no in-house ratios for this holding |
| TECX Tectonic Therapeutic Inc | NON_COMPLIANT | 1.85% | AAOIFI0.7% Usmani1.9% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic1.8% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| Crinetics Pharmaceuticals Inc | UNSCREENED | 1.69% | no in-house ratios for this holding |
| Oruka Therapeutics Inc | UNSCREENED | 1.69% | no in-house ratios for this holding |
| EQ Equillium Inc | NON_COMPLIANT | 1.69% | AAOIFI0.4% Usmani1.0% Dow Jones Islamic0.8% S&P Shariah1.0% MSCI Islamic1.0% MSCI Islamic M-Series1.0% FTSE Shariah0.0% |
| NEUROVANCE MILESTONE INTEREST | UNSCREENED | 1.66% | no in-house ratios for this holding |
| Edgewise Therapeutics Inc | UNSCREENED | 1.56% | no in-house ratios for this holding |
| AXSM Axsome Therapeutics Inc | COMPLIANT | 1.54% | AAOIFI1.9% Usmani29.5% Dow Jones Islamic2.9% S&P Shariah3.5% MSCI Islamic27.6% MSCI Islamic M-Series3.5% FTSE Shariah24.7% |
| Xenon Pharmaceuticals Inc | UNSCREENED | 1.50% | no in-house ratios for this holding |
| TSHA Taysha Gene Therapies Inc | NON_COMPLIANT | 1.48% | AAOIFI3.1% Usmani12.1% Dow Jones Islamic5.9% S&P Shariah7.4% MSCI Islamic12.0% MSCI Islamic M-Series7.4% FTSE Shariah10.5% |
| Praxis Precision Medicines Inc | UNSCREENED | 1.48% | no in-house ratios for this holding |
| EYPT EyePoint Inc | NON_COMPLIANT | 1.47% | AAOIFIfail Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| Shattuck Labs Inc | UNSCREENED | 1.42% | no in-house ratios for this holding |
| Summit Therapeutics Inc | UNSCREENED | 1.33% | no in-house ratios for this holding |
| BioCryst Pharmaceuticals Inc | UNSCREENED | 1.30% | no in-house ratios for this holding |
| Disc Medicine Inc | UNSCREENED | 1.29% | no in-house ratios for this holding |
| GPCR Structure Therapeutics Inc | NON_COMPLIANT | 1.26% | AAOIFI0.2% Usmani0.4% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.4% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| DTIL Precision BioSciences Inc | NON_COMPLIANT | 1.24% | AAOIFI2.8% Usmani4.5% Dow Jones Islamic6.4% S&P Shariah7.2% MSCI Islamic4.5% MSCI Islamic M-Series7.2% FTSE Shariah0.0% |
| ARWR Arrowhead Pharmaceuticals Inc | COMPLIANT | 1.24% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| IONS Ionis Pharmaceuticals Inc | NON_COMPLIANT | 1.22% | AAOIFI21.0% Usmani67.5% Dow Jones Islamic23.0% S&P Shariah25.1% MSCI Islamic67.5% MSCI Islamic M-Series25.1% FTSE Shariah58.8% |
| IDYA Ideaya Biosciences Inc | NON_COMPLIANT | 1.20% | AAOIFI0.8% Usmani2.2% Dow Jones Islamic1.2% S&P Shariah1.1% MSCI Islamic2.2% MSCI Islamic M-Series1.1% FTSE Shariah0.0% |
| Newamsterdam Pharma Co NV | UNSCREENED | 1.20% | no in-house ratios for this holding |
| Revolution Medicines Inc | UNSCREENED | 1.19% | no in-house ratios for this holding |
| Syndax Pharmaceuticals Inc | UNSCREENED | 1.18% | no in-house ratios for this holding |
| Sarepta Therapeutics Inc | UNSCREENED | 1.12% | no in-house ratios for this holding |
| ADPT Adaptive Biotechnologies Corp | COMPLIANT | 1.07% | AAOIFI2.0% Usmani11.8% Dow Jones Islamic3.9% S&P Shariah5.1% MSCI Islamic11.8% MSCI Islamic M-Series5.1% FTSE Shariah0.0% |
| Vaxcyte Inc | UNSCREENED | 1.07% | no in-house ratios for this holding |
| TEM Tempus AI Inc | COMPLIANT | 1.05% | AAOIFI0.7% Usmani3.5% Dow Jones Islamic0.8% S&P Shariahpass MSCI Islamic3.5% MSCI Islamic M-Seriespass FTSE Shariah0.0% |
| State Street Global Advisors | UNSCREENED | 1.01% | no in-house ratios for this holding |
| IMUX IMMUNIC | NON_COMPLIANT | 0.99% | AAOIFI0.3% Usmani0.4% Dow Jones Islamic0.5% S&P Shariah0.5% MSCI Islamic0.4% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| SGMT Sagimet Biosciences Inc | NON_COMPLIANT | 0.95% | AAOIFI0.3% Usmani0.7% Dow Jones Islamic1.0% S&P Shariah1.2% MSCI Islamic0.7% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| REGN Regeneron Pharmaceuticals Inc | COMPLIANT | 0.93% | AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8% |
| Palvella Therapeutics Inc | UNSCREENED | 0.90% | no in-house ratios for this holding |
| VCEL Vericel Corp | COMPLIANT | 0.87% | AAOIFI4.0% Usmani18.5% Dow Jones Islamic4.4% S&P Shariah4.4% MSCI Islamic18.4% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| Allogene Therapeutics Inc | UNSCREENED | 0.82% | no in-house ratios for this holding |
| AMGN Amgen Inc | COMPLIANT | 0.80% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Biohaven Ltd | UNSCREENED | 0.79% | no in-house ratios for this holding |
| GRAL GRAIL Inc | NON_COMPLIANT | 0.77% | AAOIFI2.5% Usmani3.2% Dow Jones Islamic4.7% S&P Shariahfail MSCI Islamic3.2% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| Codexis Inc | UNSCREENED | 0.77% | no in-house ratios for this holding |
| SPRY ARS Pharmaceuticals Inc | NON_COMPLIANT | 0.76% | AAOIFI17.3% Usmani38.7% Dow Jones Islamic8.7% S&P Shariah9.8% MSCI Islamic38.7% MSCI Islamic M-Series9.8% FTSE Shariah38.7% |
| Amylyx Pharmaceuticals Inc | UNSCREENED | 0.74% | no in-house ratios for this holding |
| Corbus Pharmaceuticals Holdings Inc | UNSCREENED | 0.74% | no in-house ratios for this holding |
| JBIO Jade Biosciences Inc | NON_COMPLIANT | 0.73% | AAOIFI0.0% Usmani0.1% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.1% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| ALNY Alnylam Pharmaceuticals Inc | COMPLIANT | 0.72% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| CYTK Cytokinetics Inc | NON_COMPLIANT | 0.71% | AAOIFI3.9% Usmani20.7% Dow Jones Islamic5.9% S&P Shariah6.2% MSCI Islamic20.7% MSCI Islamic M-Series6.2% FTSE Shariah14.3% |
| ProQR Therapeutics NV | UNSCREENED | 0.71% | no in-house ratios for this holding |
| Cogent Biosciences Inc | UNSCREENED | 0.70% | no in-house ratios for this holding |
| RCUS Arcus Biosciences Inc | COMPLIANT | 0.69% | AAOIFI3.0% Usmani12.3% Dow Jones Islamic5.9% S&P Shariah6.5% MSCI Islamic12.3% MSCI Islamic M-Series6.5% FTSE Shariah10.9% |
| IMUX Immunic Inc | NON_COMPLIANT | 0.68% | AAOIFI0.3% Usmani0.4% Dow Jones Islamic0.5% S&P Shariah0.5% MSCI Islamic0.4% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| WGS GeneDx Holdings Corp | COMPLIANT | 0.67% | AAOIFI4.7% Usmani20.1% Dow Jones Islamic3.9% S&P Shariah5.5% MSCI Islamic20.1% MSCI Islamic M-Series5.5% FTSE Shariah20.1% |
| ARQT Arcutis Biotherapeutics Inc | COMPLIANT | 0.66% | AAOIFI3.8% Usmani23.4% Dow Jones Islamic5.0% S&P Shariah6.5% MSCI Islamic23.4% MSCI Islamic M-Series6.5% FTSE Shariah22.3% |
| OCSAW Oculis Holding AG | NON_COMPLIANT | 0.65% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.0% MSCI Islamic M-Series— FTSE Shariah0.0% |
| CURASEN THERAPEUTICS, INC. | UNSCREENED | 0.63% | no in-house ratios for this holding |
| RYTM Rhythm Pharmaceuticals Inc | NON_COMPLIANT | 0.61% | AAOIFI1.6% Usmani25.1% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic25.1% MSCI Islamic M-Series2.5% FTSE Shariah24.3% |
| Mineralys Therapeutics Inc | UNSCREENED | 0.60% | no in-house ratios for this holding |
| Inventiva SACA | UNSCREENED | 0.60% | no in-house ratios for this holding |
| MAZE Maze Therapeutics Inc | COMPLIANT | 0.59% | AAOIFI4.2% Usmani11.4% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic11.4% MSCI Islamic M-Seriesfail FTSE Shariah7.3% |
| IMUX IMMUNIC | NON_COMPLIANT | 0.59% | AAOIFI0.3% Usmani0.4% Dow Jones Islamic0.5% S&P Shariah0.5% MSCI Islamic0.4% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| PALI Palisade Bio Inc | NON_COMPLIANT | 0.58% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Definium Therapeutics Inc | UNSCREENED | 0.54% | no in-house ratios for this holding |
| KRYS Krystal Biotech Inc | NON_COMPLIANT | 0.54% | AAOIFI0.1% Usmani0.6% Dow Jones Islamic0.1% S&P Shariah0.2% MSCI Islamic0.6% MSCI Islamic M-Series0.2% FTSE Shariah0.0% |
| JAZZ Jazz Pharmaceuticals PLC | COMPLIANT | 0.54% | AAOIFI31.0% Usmani39.7% Dow Jones Islamic44.2% S&P Shariah48.5% MSCI Islamic39.7% MSCI Islamic M-Series48.5% FTSE Shariah39.3% |
| Sionna Therapeutics Inc | UNSCREENED | 0.53% | no in-house ratios for this holding |
| IMUX IMMUNIC INC. | NON_COMPLIANT | 0.52% | AAOIFI0.3% Usmani0.4% Dow Jones Islamic0.5% S&P Shariah0.5% MSCI Islamic0.4% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| Relay Therapeutics Inc | UNSCREENED | 0.51% | no in-house ratios for this holding |
| Lexeo Therapeutics Inc | UNSCREENED | 0.46% | no in-house ratios for this holding |
| HOTSPOT THERAPEUTICS, INC. | UNSCREENED | 0.45% | no in-house ratios for this holding |
| ASND Ascendis Pharma A/S | COMPLIANT | 0.45% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| LENZ LENZ Therapeutics Inc | NON_COMPLIANT | 0.41% | AAOIFI0.3% Usmani0.2% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.2% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| NBIX Neurocrine Biosciences Inc | COMPLIANT | 0.40% | AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| IMUX IMMUNIC INC. | NON_COMPLIANT | 0.40% | AAOIFI0.3% Usmani0.4% Dow Jones Islamic0.5% S&P Shariah0.5% MSCI Islamic0.4% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| Avalo Therapeutics Inc | UNSCREENED | 0.35% | no in-house ratios for this holding |
| ELOX ELOXX PHARMACEUTICALS, INC. | NON_COMPLIANT | 0.33% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| AgomAb Therapeutics NV | UNSCREENED | 0.32% | no in-house ratios for this holding |
| THIRD ARC BIO, INC | UNSCREENED | 0.32% | no in-house ratios for this holding |
| Assembly Biosciences Inc | UNSCREENED | 0.31% | no in-house ratios for this holding |
| IMTX Immatics NV | NON_COMPLIANT | 0.27% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| VRTX Vertex Pharmaceuticals Inc | COMPLIANT | 0.27% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| ALKS Alkermes PLC | COMPLIANT | 0.27% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ELOX Eloxx Pharmaceuticals Inc | NON_COMPLIANT | 0.26% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| QUELL THERAPEUTICS | UNSCREENED | 0.26% | no in-house ratios for this holding |
| GLYCOMINE, INC. | UNSCREENED | 0.25% | no in-house ratios for this holding |
| CRYSTALYS THERAPEUTICS SER A | UNSCREENED | 0.25% | no in-house ratios for this holding |
| ARBOR BIOTECHNOLOGIES | UNSCREENED | 0.23% | no in-house ratios for this holding |
| SKYHAWK THERAPEUTICS, INC. | UNSCREENED | 0.23% | no in-house ratios for this holding |
| QLARIS BIO, INC. | UNSCREENED | 0.22% | no in-house ratios for this holding |
| DTIL PRECISION BIOSCIENCES | NON_COMPLIANT | 0.22% | AAOIFI2.8% Usmani4.5% Dow Jones Islamic6.4% S&P Shariah7.2% MSCI Islamic4.5% MSCI Islamic M-Series7.2% FTSE Shariah0.0% |
| ENDEAVOR BIOMEDICINES, INC. | UNSCREENED | 0.20% | no in-house ratios for this holding |
| RCKT Rocket Pharmaceuticals Inc | NON_COMPLIANT | 0.20% | AAOIFI0.8% Usmani5.9% Dow Jones Islamic0.5% S&P Shariah0.3% MSCI Islamic0.8% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| SEISMIC THERAPEUTICS, INC. | UNSCREENED | 0.18% | no in-house ratios for this holding |
| Seaport Therapeutics Inc | UNSCREENED | 0.17% | no in-house ratios for this holding |
| NUVIG THERAPEUTICS, INC | UNSCREENED | 0.17% | no in-house ratios for this holding |
| AMOLYT MILESTONE | UNSCREENED | 0.16% | no in-house ratios for this holding |
| ENGRAIL THERAPEUTICS INC. SERI | UNSCREENED | 0.15% | no in-house ratios for this holding |
| WVE WaVe Life Sciences Ltd | NON_COMPLIANT | 0.15% | AAOIFI3.9% Usmani7.8% Dow Jones Islamic2.9% S&P Shariah3.6% MSCI Islamic7.8% MSCI Islamic M-Series3.6% FTSE Shariah0.0% |
| INFINANT HEALTH | UNSCREENED | 0.14% | no in-house ratios for this holding |
| HOTSPOT THERAPEUTICS, INC. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| SpyGlass Pharma Inc | UNSCREENED | 0.13% | no in-house ratios for this holding |
| EVMN EVOMMUNE | NON_COMPLIANT | 0.11% | AAOIFI1.7% Usmani2.9% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic2.5% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| ATALANTA THERAPEUTICS | UNSCREENED | 0.11% | no in-house ratios for this holding |
| INCENDIA THERAPEUTICS, INC. | UNSCREENED | 0.11% | no in-house ratios for this holding |
| INVETX MILESTONE INTEREST | UNSCREENED | 0.10% | no in-house ratios for this holding |
| ATALANTA THERAPEUTICS | UNSCREENED | 0.10% | no in-house ratios for this holding |
| CURASEN THERAPEUTICS, INC. | UNSCREENED | 0.10% | no in-house ratios for this holding |
| ARBOR BIOTECHNOLOGIES | UNSCREENED | 0.09% | no in-house ratios for this holding |
| KLRA Kailera Therapeutics Inc | NON_COMPLIANT | 0.08% | AAOIFI0.5% Usmani0.8% Dow Jones Islamic— S&P Shariah— MSCI Islamic0.8% MSCI Islamic M-Series— FTSE Shariah0.0% |
| Odyssey Therapeutics Inc | UNSCREENED | 0.08% | no in-house ratios for this holding |
| RECODE THERAPEUTICS | UNSCREENED | 0.07% | no in-house ratios for this holding |
| ABCURO, INC. | UNSCREENED | 0.07% | no in-house ratios for this holding |
| CURASEN THERAPEUTICS CONV PN | UNSCREENED | 0.06% | no in-house ratios for this holding |
| Avalyn Pharma Inc | UNSCREENED | 0.06% | no in-house ratios for this holding |
| ENDEAVOR BIOMEDICINES INC. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| HIBERCELL,INC. SERIES C | UNSCREENED | 0.05% | no in-house ratios for this holding |
| Hemab Therapeutics Holdings Inc | UNSCREENED | 0.05% | no in-house ratios for this holding |
| HOTSPOT THERAPEUTICS, INC. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| HIBERCELL INC. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| HIBERCELL BRIDGE NOTE | UNSCREENED | 0.05% | no in-house ratios for this holding |
| Options Clearing Corp. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| ABCURO INC. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| Incendia Therapeutics, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| HIBERCELL, INC. SERIES B | UNSCREENED | 0.04% | no in-house ratios for this holding |
| INCENDIA THERAPEUTICS, INC. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| BIOTHERYX, INC. SERIES E | UNSCREENED | 0.04% | no in-house ratios for this holding |
| AVICEDA THERAPEUTICS | UNSCREENED | 0.03% | no in-house ratios for this holding |
| HIBERCELL, INC. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| QLARIS BIO, INC. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| CURASEN THERAPEUTICS, INC. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| QNRX Quoin Pharmaceuticals Ltd | NON_COMPLIANT | 0.02% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| QLARIS BIO BRIDGE NOTE | UNSCREENED | 0.02% | no in-house ratios for this holding |
| OCULIS HOLDINGS AG | UNSCREENED | 0.02% | no in-house ratios for this holding |
| RECODE THERAPEUTICS, INC. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| INCENDIA BRIDGE NOTE 5/2026 | UNSCREENED | 0.01% | no in-house ratios for this holding |
| Options Clearing Corp. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| Options Clearing Corp. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| CONTRA CHINOOK THERAPE | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Options Clearing Corp. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Options Clearing Corp. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| CONTRA FUSION PHARMACE | UNSCREENED | 0.00% | no in-house ratios for this holding |
| TWST Twist Bioscience Corp | COMPLIANT | 0.00% | AAOIFI1.1% Usmani13.9% Dow Jones Islamic3.2% S&P Shariah3.5% MSCI Islamic13.9% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| IO LIGHT HOLDINIGS, INC. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| PRIOTHERA LIMITED | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Willow Laboratories Inc. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| HIBERCELL INC. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| HIBERCELL, INC. SERIES C | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Afferent Milestone Interest | UNSCREENED | 0.00% | no in-house ratios for this holding |
| ETHISMOS RESEARCH, INC. MILEST | UNSCREENED | 0.00% | no in-house ratios for this holding |
| AMPHIVENA MILESTONE INTEREST | UNSCREENED | 0.00% | no in-house ratios for this holding |
| RECODE THERAPEUTICS, INC. | UNSCREENED | 0.00% | no in-house ratios for this holding |
| HIBERCELL INC. | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 7 points of portfolio weight — 8.0% of it passes AAOIFI, 1.1% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 8.0% ratios fail on 24.4% 67.8% not rated under AAOIFI
ratios pass on 3.4% ratios fail on 26.9% 69.9% not rated under Usmani
ratios pass on 7.7% ratios fail on 21.5% 71.0% not rated under Dow Jones Islamic
ratios pass on 7.7% ratios fail on 19.8% 72.6% not rated under S&P Shariah
ratios pass on 1.1% ratios fail on 32.1% 67.0% not rated under MSCI Islamic
ratios pass on 7.7% ratios fail on 20.1% 72.4% not rated under MSCI Islamic M-Series
ratios pass on 3.4% ratios fail on 26.9% 69.9% not rated under FTSE Shariah
46 of 158 listed holdings carry our own per-methodology verdicts (41% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 39 (34% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| PSNL Personalis Inc | 3.00% |
| TECX Tectonic Therapeutic Inc | 1.85% |
| EQ Equillium Inc | 1.69% |
| TSHA Taysha Gene Therapies Inc | 1.48% |
| EYPT EyePoint Inc | 1.47% |
| GPCR Structure Therapeutics Inc | 1.26% |
| DTIL Precision BioSciences Inc | 1.24% |
| IONS Ionis Pharmaceuticals Inc | 1.22% |
| IDYA Ideaya Biosciences Inc | 1.20% |
| IMUX IMMUNIC | 0.99% |
Methodology breakdown computing — it will appear here on its own.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
abrdn Life Sciences Investors (HQL) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Computing the full ratio and business-activity breakdown for HQL — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 36.40 | NEUTRAL |
| Stochastic %K (14) | 27.25 | NEUTRAL |
| CCI (20) | -60.21 | NEUTRAL |
| Williams %R (14) | -72.75 | NEUTRAL |
| MACD (12,26,9) | -0.05 | SELL |
| ROC (10) | -5.25 | SELL |
| Momentum (10) | -0.99 | SELL |
| EMA (10) | 18.06 | SELL |
| SMA (10) | 17.93 | SELL |
| EMA (20) | 18.57 | SELL |
| SMA (20) | 18.66 | SELL |
| EMA (30) | 18.91 | SELL |
| SMA (30) | 19.26 | SELL |
| EMA (50) | 19.15 | SELL |
| SMA (50) | 19.83 | SELL |
| EMA (100) | 18.81 | SELL |
| SMA (100) | 18.98 | SELL |
| EMA (200) | 17.61 | BUY |
| SMA (200) | 17.41 | BUY |
Financial Services · Asset Management
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 42 |
| ⏰ 4H | BEARISH | 26 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-06 · Asset managers net 906615 (+2612)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.